Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
The New York Proton Center
Stemline Therapeutics, Inc.
Eastern Cooperative Oncology Group
Eli Lilly and Company
Mayo Clinic
University of Illinois at Chicago
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
BBB-Therapeutics B.V.
M.D. Anderson Cancer Center
University of California, San Francisco
National Cancer Institute (NCI)
Novartis
Tufts Medical Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)